CNS Pharmaceuticals (CNSP) Expected to Post Earnings on Monday

CNS Pharmaceuticals (NASDAQ:CNSP) is expected to post its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($8.82) by $1.52.

CNS Pharmaceuticals Stock Down 2.6%

Shares of CNSP stock opened at $5.24 on Monday. The firm has a 50 day moving average of $4.95 and a two-hundred day moving average of $4.21. The stock has a market capitalization of $7.65 million, a PE ratio of -0.18 and a beta of 3.05. CNS Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $10.59.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.00.

Insiders Place Their Bets

In other news, Director Faith L. Charles purchased 7,100 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the completion of the purchase, the director directly owned 7,100 shares of the company’s stock, valued at $34,009. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.01% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CNS Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Boothbay Fund Management LLC purchased a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth $71,000. Ikarian Capital LLC purchased a new position in CNS Pharmaceuticals in the fourth quarter valued at $241,000. Finally, Armistice Capital LLC acquired a new stake in CNS Pharmaceuticals in the second quarter valued at $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.